Chemotherapeutic Drugs-Induced Pyroptosis Mediated by Gasdermin E Promotes the Progression and Chemoresistance of Pancreatic Cancer

Shumin Li,Ming Yue,Haiyan Xu,Xiaofei Zhang,Tiebo Mao,Ming Quan,Jingyu Ma,Yanling Wang,Weiyu Ge,Yongchao Wang,Shengbai Xue,Daiyuan Shentu,Jiujie Cui,Liwei Wang

DOI: https://doi.org/10.1016/j.canlet.2023.216206

IF: 9.756

2023-01-01

Cancer Letters

Abstract:Pyroptosis is closely associated with cancer development; however, the role of pyroptosis in pancreatic ductal adenocarcinoma (PDAC), a fatal malignant tumour with a poor overall survival rate, remains elusive. Here, we explored the mechanism of chemotherapy-induced pyroptosis and elucidated the role of pyroptosis in mediating PDAC progression and chemoresistance. The results demonstrated first- and second-line chemotherapeutic drugs against PDAC, including gemcitabine, irinotecan, 5-fluorouracil, paclitaxel, and cisplatin, induced concurrent pyroptosis and apoptosis. During this process, gasdermin E (GSDME) was cleaved by activated caspase-3, which was accompanied by pro-apoptotic caspase-7/8 activation. GSDME knockdown switched pyroptosis to apoptosis, decreased invasion and migration, and enhanced the sensitivity of PDAC cells to chemotherapy in vitro and in vivo. GSDME was highly expressed in PDAC tissues and positively correlated with histological differentiation and vascular invasion. Furthermore, cells that survived pyroptosis promoted proliferation and invasion and impaired the chemosensitivity of PDAC cells, which was attenuated by the GSDME knockdown. Our findings demonstrated that chemotherapeutics against PDAC induce GSDME-dependent pyroptosis, and GSDME expression positively correlated with PDAC progression and chemoresistance. Targeting GSDME may be a novel approach to overcoming chemoresistance in PDAC.